Lumos Diagnostics has landed a US$767,800 purchase order for its FebriDx rapid test from PHASE Scientific, marking a key step in commercialising its FDA-approved product ahead of the US flu season.
- US$767,800 FebriDx order from PHASE Scientific
- Order linked to US$5 million FDA CLIA waiver prepayment
- Delivery scheduled through October 2026
- Order fulfills Year 1 minimum purchase commitment
- Revenue recognised upon shipment
Significant Purchase Order Follows FDA CLIA Waiver
Lumos Diagnostics Holdings Ltd (ASX:LDX) has secured a substantial US$767,800 purchase order for its FebriDx rapid, point-of-care diagnostic test from its exclusive US distributor, PHASE Scientific. This initial order is tied directly to the US$5 million prepayment milestone Lumos received after the FDA granted a CLIA waiver for FebriDx in March 2026, a regulatory approval that significantly eases the test's use in US healthcare settings.
The order represents a portion of the Year 1 minimum order quantity commitment under the distribution agreement with PHASE Scientific and will be credited against the prepayment balance, which remains available to support future orders. Lumos will recognise revenue progressively as shipments are delivered through to October 2026.
Commercial Momentum Ahead of Flu Season
CEO Doug Ward highlighted the timing of the order as critical, coinciding with US healthcare providers gearing up for the upcoming flu season. The FebriDx test, designed for rapid differentiation of acute respiratory infections, is positioned to meet heightened demand for quick diagnostics in urgent care and outpatient settings.
This development builds on Lumos's expanding footprint in the US market, where FebriDx is gaining traction across urgent care networks. The company has previously reported a strong surge in FebriDx sales following the CLIA waiver, alongside milestone payments and growing adoption at healthcare sites nationwide.
Revenue Recognition and Future Orders
The delivery schedule for the current order extends through to October 2026, with revenue recognised upon shipment. While the announcement does not specify the volume or timing of subsequent orders beyond this period, the prepayment balance held by Lumos provides a financial buffer to support ongoing supply commitments.
Investors will be watching how Lumos leverages this FDA regulatory milestone to convert prepayment funds into sustained revenue growth and broader market penetration in the US, a critical market for the company’s point-of-care diagnostic ambitions.
Bottom Line?
Lumos’s first FebriDx order under the FDA CLIA waiver prepayment signals solid early commercial traction, but sustained revenue growth will hinge on follow-up orders beyond October 2026.
Questions in the middle?
- Will Lumos convert the remaining US$4.2 million prepayment into firm orders this fiscal year?
- How rapidly will FebriDx adoption scale across US urgent care and outpatient networks?
- What impact will the upcoming flu season have on FebriDx sales momentum and revenue recognition?